ClinicalTrials.gg
CompletedNCT07344376Updated Jan 15, 2026

An Extension Study to Assess the Long-term Safety and Efficacy of Hunterase (Idursulfase Beta)

A Phase 3 interventional study of Hunterase in MPS II, Hunter Syndrome (MPS II) and Hunter Syndrome, sponsored by GC Biopharma Corp. Completed at 1 site in South Korea. Open to male participants. Per ClinicalTrials.gov, last updated 2026-01-15.

Sponsored by GC Biopharma Corp · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 7 years 5 months after the study started (first participant enrolled May 2018, registered Nov 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Sex
Male
01

Study summary

The objective of this study is to assess the long-term safety and efficacy of Hunterase for approximately 1 year in subjects who completed the end of study (EOS) visit (Visit 54) tests in the Phase 3 Hunterase study and patients who received Hunterase for more than 6 months

02

Conditions studied

  • MPS II
  • Hunter Syndrome (MPS II)
  • Hunter Syndrome
  • Hunterase
  • GC1111

Keywords

  • Hunterase
  • GC1111
  • GC Biopharma
  • Long-term study
  • extension study
03

In context

Sudden Infant Death

80 studies on the registry are indexed under Sudden Infant Death; 13 are open to participants now.

This study's enrollment of 30 is below the median of 60 across 51 interventional studies indexed under Sudden Infant Death.

Browse Sudden Infant Death studies →

Lead sponsor

GC Biopharma Corp is the lead sponsor of 16 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject diagnosed with Hunter syndrome (MPS II) who completed activities at the EOS visit (Visit 54) in the GC1111_P3 study
  2. (Subject who did not participate in the GC1111_P3 study) Subject diagnosed with Hunter syndrome (MPS II) who received Hunterase for more than 6 months
  3. (Subjects who did not participate in the GC1111_P3 study) Males aged ≥ 5
  4. form voluntarily signed by the subject or by a legally acceptable representative
  5. Subject who agrees to use

Exclusion criteria

Exclusion Criteria:

  1. Subject with to any of the ingredients of the product
  2. Subject impossible to perform follow-up observation of the safety
  3. Subject who received the treatment with another investigational product within 14 days prior to the start of study drug
  4. Subject who plans to be treated with another investigational product during the study period
  5. Subject who has history of tracheostomy, bone marrow transplant, or cord blood transplant
  6. Any other inappropriate conditions for study participation at the investigator's discretion
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Other
    Hunterase

    Single arm

    Drug: Hunterase

Interventions

  • 0.5mg/kg weekly IV administration

    Also known as: GC1111

06

What researchers measure

Primary outcomes

  1. Laboratory tests (CBC, Chemistry, Urinanalysis)

    Abnormality of Laboratory tests results

    Time frame: Every visit until 12months

  2. Physical examination

    Abnormality of physical examination

    Time frame: Every visit until 12months

  3. Adverse Event

    occurence, grade

    Time frame: Every visit until 12months

  4. Electrocardiography

    Abnormality of ECG results

    Time frame: Every 6 months until 12months

Secondary outcomes

  1. 6-minute walk test

    Mean, Change and percent change of 6-minute walk test

    Time frame: Every 4months until 12months

  2. Urine GAG (Heparan sulfate, Dermatan sulfate)

    Mean, Change and percent change of Urine HS/DS

    Time frame: Every visit until 12months

07

Study locations

1 site
  • Samsung Medical Center
    Seoul, South Korea
08

References and documents

Publications

  • Im M, Song A, Park H, Kim J, Kim C, Noh ES, Bae GY, Sung J, Hwang J, Ahn YJ, Kim H, Oh Y, Kim B, Cho SY. Sustained clinical benefit of idursulfase beta in mucopolysaccharidosis II: two-year experience from a phase 3 extension study including patients switched from idursulfase. Orphanet J Rare Dis. 2026 Jul 9. doi: 10.1186/s13023-026-04492-2. Online ahead of print. PubMed 42421116 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2018 to primary completion in Dec 2022, 55 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Jan 15, 2026
StartActual
May 23, 2018
Primary completionActual
Dec 30, 2022
CompletionActual
Dec 30, 2022
Last update
Jan 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07344376
Lead sponsor
GC Biopharma Corp
Responsible party
Sponsor
First posted
Jan 15, 2026
Start date
May 23, 2018
Primary completion
Dec 30, 2022
Completion
Dec 30, 2022
Last update
Jan 15, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Idursulfase beta

Start the discussion